General Info

GlycoMimetics develops novel small molecule therapeutics based upon the roles that carbohydrates play in biological processes. The company believes that carbohydrate mimics, or glycomimetic compounds, represent a new class of drugs. It has identified some compounds with potential therapeutic utility. One class has potential in the treatment of infectious diseases with a novel mechanism of action; the second is a class of anti-inflammatory compounds that have been shown to reduce key measures of inflammation. One of GMI s lead opportunities is to treat or prevent infections caused by Pseudomonas aeruginosa. Its objective in this program is to develop a drug that would be used in conjunction with antibiotics against chronic infections that have failed to respond to antibiotic treatment. The company also has compounds that inhibit selectin binding. Its initial focus in this program is to develop a product to treat acute exacerbations of asthma and chronic obstructive pulmonary disease. GlycoMimetics is headquartered in Gaithersburg, Md.